Skip to main content
. 2021 Mar 16;60(12):5785–5794. doi: 10.1093/rheumatology/keab254

Table 4.

Incidence of MTX and LEF dose reduction

MTX
LEF
Outcome Events (n) Person-time (years) Event rate (95% CI) /1000 person-years Events (n) Person-time (years) Event rate (95%CI) /1000 person-time
Any abnormal blood-test result
 Ever 142 6679 21.26 (18.04, 25.06) 47 3151 14.92 (11.21, 19.85)
 First 12 months 77 2764 27.86 (22.29, 34.84) 31 1176 26.36 (18.54, 37.48)
 After first 12 months 65 3915 16.60 (13.05, 21.13) 16 1975 8.10 (4.97, 13.20)
Leucopenia (WBC <3.5×109/l)
 Ever 36 6785 5.31 (3.83, 7.36) 19 3185 5.97 (3.80, 9.35)
 First 12 months 19 2779 6.84 (4.36, 10.72) 14 1181 11.85 (7.02, 20.02)
 After first 12 months 17 4006 4.24 (2.64, 6.82) 5 2004 2.50 (1.04, 5.99)
Neutropenia (Neutrophil <1.6×109/l)
 Ever 21 6798 3.09 (2.01, 4.74) 23 3177 7.24 (4.81, 10.89)
 First 12 months 14 2779 5.04 (2.98, 8.51) 13 1182 11.00 (6.39, 18.94)
 After first 12 months 7 4019 4.24 (2.64, 6.82) 10 1995 5.04 (2.71, 9.35)
Thrombocytopenia (Platelet <140×109/l)
 Ever 26 6784 3.83 (2.61, 5.63) 9 3200 2.81 (1.46, 5.41)
 First 12 months 11 2782 3.95 (2.19, 7.14) 8 1183 6.77 (3.38, 13.53)
 After first 12 months 15 4002 3.75 (2.26, 6.21) –/– –/– 0.50 (0.07, 3.52)
ALT or AST >100 IU/l
 Ever 56 6758 8.29 (6.38, 10.77) 9 3197 2.82 (1.46, 5.41)
 First 12 months 31 2776 11.17 (7.85, 15.88) 7 1184 5.91 (2.82, 12.40)
 After first 12 months 25 3982 6.28 (4.25, 9.28) –/– 2013 1.00 (0.25, 3.97)
CKD progression/creatinine + >26 μmol/l
 Ever 33 6787 4.86 (3.46, 6.84) 6 3199 1.88 (0.84, 4.17)
 First 12 months 19 2777 6.84 (4.36, 10.73) –/– –/– 1.69 (0.42, 6.76)
 After first 12 months 14 4010 3.49 (2.07, 5.89) –/– –/– 1.99 (0.75, 5.28)

WBC: white blood cells